High S100A2 expression in keratinocytes in patients with drug eruption.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Chemotactic Factors/*biosynthesis ; Drug Eruptions/*metabolism ; Gene Expression Regulation/*drug effects ; Keratinocytes/*metabolism ; Oligopeptides/*pharmacology ; S100 Proteins/*biosynthesis; Aged ; Drug Eruptions/pathology ; Female ; Hepacivirus/metabolism ; Hepatitis C/drug therapy ; Hepatitis C/metabolism ; Hepatitis C/pathology ; Humans ; Keratinocytes/pathology ; Male ; Middle Aged
    • Abstract:
      Telaprevir used as a protease inhibitor against hepatitis C virus is frequently associated with cutaneous adverse reactions. To explore a histological biomarker of cutaneous adverse events induced by telaprevir, we systematically searched for genes that were dysregulated by telaprevir in normal human epidermal keratinocytes (NHEKs). Microarray analysis and real-time polymerase chain reaction (PCR) revealed the significant increase in the expression of S100 calcium-binding protein A2 (S100A2) gene following treatment of NHEKs with telaprevir. Immunohistochemical analysis demonstrated that the expression of S100A2 was dominant in the spinous layer of the epidermis in patients with telaprevir-mediated severe-type drug eruptions and limited to the basal layer of the epidermis in healthy subjects. Furthermore, S100A2 expression increased after treatment with trichloroethylene and other medications, and the degree of S100A2 expression correlated with the severity of cutaneous adverse events. S100A2 expression also significantly increased in the skin of patients with atopic dermatitis and psoriasis. Taken together, S100A2 is highly expressed in the epidermis under inflammatory conditions and drug eruptions and may serve as a marker for keratinocyte damage in response to any inflammatory or toxic condition.
    • References:
      Arch Dermatol. 2001 Mar;137(3):274-6. (PMID: 11255324)
      Clin Cancer Res. 2012 Jul 15;18(14):3772-9. (PMID: 22648272)
      Exp Dermatol. 2008 Feb;17(2):81-90. (PMID: 18034836)
      Tuberc Respir Dis (Seoul). 2014 Feb;76(2):75-9. (PMID: 24624216)
      Yonsei Med J. 2012 Jan;53(1):231-5. (PMID: 22187259)
      N Engl J Med. 2010 Apr 8;362(14):1292-303. (PMID: 20375406)
      Cell Calcium. 1997 Oct;22(4):243-54. (PMID: 9481475)
      Am J Nephrol. 1990;10(3):222-30. (PMID: 2382683)
      Science. 2009 Apr 17;324(5925):392-7. (PMID: 19286519)
      Lancet. 1947 Aug 23;2(6469):276. (PMID: 20257905)
      J Invest Dermatol. 2011 Nov;131(11):2178-85. (PMID: 21734715)
      Science. 2011 Dec 16;334(6062):1524-9. (PMID: 22096102)
      Tumour Biol. 2014 Aug;35(8):7327-33. (PMID: 24863947)
      J Korean Med Sci. 2018 Apr 02;33(14):e106. (PMID: 29607632)
      J Allergy Clin Immunol. 2011 Apr;127(4):954-64.e1-4. (PMID: 21388663)
      Nat Immunol. 2002 Jul;3(7):673-80. (PMID: 12055625)
      BMC Genomics. 2009 Jun 17;10:269. (PMID: 19534766)
      J Invest Dermatol. 2010 Nov;130(11):2683-6. (PMID: 20613776)
      Exp Ther Med. 2016 Aug;12(2):895-900. (PMID: 27446293)
      Nat Med. 2008 Dec;14(12):1343-50. (PMID: 19029983)
      J Dermatol Sci. 2006 May;42(2):91-9. (PMID: 16431082)
      Immunology. 1992 Feb;75(2):257-63. (PMID: 1551688)
      Int Arch Occup Environ Health. 2007 Apr;80(5):357-70. (PMID: 17106739)
      Contact Dermatitis. 1984 May;10(5):270-6. (PMID: 6734188)
      Eur J Gastroenterol Hepatol. 2014 Feb;26(2):244-5. (PMID: 24366454)
      J Hepatol. 2012 Jan;56(1):78-84. (PMID: 21827730)
      Hepatology. 2014 Jan;59(1):46-8. (PMID: 23813604)
      PLoS One. 2008 Jul 16;3(7):e2737. (PMID: 18648529)
      Histol Histopathol. 2002 Jan;17(1):123-30. (PMID: 11813862)
      J Cell Biol. 2001 Nov 26;155(5):747-54. (PMID: 11724817)
      Nat Commun. 2019 Apr 3;10(1):1523. (PMID: 30944313)
    • Accession Number:
      0 (Chemotactic Factors)
      0 (Oligopeptides)
      0 (S100 Proteins)
      0 (S100A2 protein, human)
      655M5O3W0U (telaprevir)
    • Publication Date:
      Date Created: 20210322 Date Completed: 20211208 Latest Revision: 20211214
    • Publication Date:
      20221213
    • Accession Number:
      PMC7943585
    • Accession Number:
      10.1038/s41598-021-85009-8
    • Accession Number:
      33750880